PT - JOURNAL ARTICLE AU - Magfira, Nadya AU - Helda, TI - Correlation between adult tobacco smoking prevalence and mortality of Coronavirus Disease-19 across the world AID - 10.1101/2020.12.01.20241596 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.01.20241596 4099 - http://medrxiv.org/content/early/2020/12/03/2020.12.01.20241596.short 4100 - http://medrxiv.org/content/early/2020/12/03/2020.12.01.20241596.full AB - Background and aim Coronavirus disease 2019 (COVID-19) is a global pandemic spreading worldwide. Limited studies showed that smokers were at higher risk of having severe complications and higher mortality. This study aims to analyze the possible correlation between adult tobacco smoking prevalence and COVID-19 mortality all over the world.Methods This is a correlation study, we conducted a linear regression to analyse the correlation between smoking prevalence data in adults and COVID-19 Case Fatality Ratio (CFR) in countries with 1000 confirmed COVID-19 cases on May 3, 2020.Results Seventy-five country included with median CFR 3.66%. There are no relationships between adult male or female smoking prevalence with COVID-19 mortality in all over the countries. The multivariate analysis showed p-values of 0.823 and 0.910 for male and female smoking prevalence respectively. However, in lower-middle-income countries (LMIC), there is a positive correlation between the prevalence of adult male smoking with the lethality of COVID-19. Each percentage point increase in adult male smoking prevalence caused a CFR of COVID-19 increase by 0.08% (95% CI 0.00%-0.15%, p=0.041).Conclusions A correlation was found between the prevalence of adult male smoking and the CFR of COVID-19 in lower middle-income countries. Based on these findings, strengthening tobacco control policies is needed to reduce the impact of the COVID-19 pandemic especially in LMIC. Further researches are still needed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not for profit sectorAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used public use data set, I confirm all relevant ethical guidelines have been followed and no necessary IRB approval neededAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are openly available in WHO situation data, WHO Global Health Observatory and Repository, and The World Bank data https://apps.who.int/gho/data/node.main.65. https://data.worldbank.org/indicator/SH.XPD.CHEX.GD.ZS. https://apps.who.int/gho/data/node.main.A867?lang=en.